Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

909

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2017

Conditions
Dry Eye SyndromesKeratoconjunctivitis Sicca
Interventions
DRUG

KPI-121 0.25% Ophthalmic Suspension

DRUG

Vehicle of KPI-121 0.25% Ophthalmic Suspension

Trial Locations (62)

10013

Raymond Fong, MDPC, New York

11570

Ophthalmic Consultants of Long Island, Rockville Centre

16066

Scott & Christie and Associates, PC, Cranberry Township

18702

Bucci Laser Vision Institute, Wilkes-Barre

18704

Eye Care Specialists, Kingston

23502

Virginia Eye Consultants, Norfolk

26505

Regional Eye Associates, Morgantown

27101

James D Branch MD, Winston-Salem

27262

Cornerstone Eye Care, High Point

30260

Eye Care Centers Management, Inc. (Clayton Eye Center), Morrow

32174

International Eye Associates PA, Ormond Beach

33603

Perez Eye Center/International Research Center, Tampa

33773

Shettle Eye Research, Inc, Largo

33805

Central Florida Eye Associates, Lakeland

34613

Hernando Eye Institute, Brooksville

37215

Toyos Clinic, Nashville

37411

Chattanooga Eye Institute, P.C., Chattanooga

38119

Total Eye Care, PA, Memphis

40206

The Eye Care Institute, Louisville

40217

Taustine Eye Center, Louisville

40509

Koffler Vision Group, Lexington

41017

Cincinnati Eye Institute, Edgewood

43082

Comprehensive Eye Care of Central Ohio, Westerville

46260

Price Vision Group, Indianapolis

47150

John-Kenyon American Eye Institute, New Albany

55431

Minnesota Eye Consultants, PA, Bloomington

60169

Chicago Cornea Consultants, Ltd., Hoffman Estates

63090

Comprehensive Eye Care, Ltd. / Vision Research Institute, LLC, Washington

63128

Tekwani Vision Center, St Louis

64111

Tauber Eye Center, Kansas City

72401

NEA Baptist Clinic, Jonesboro

77024

Houston Eye Associates, Houston

77034

Advanced Laser Vision & Surgical Institute, Intouch Clinical Research Center, Houston

77055

Whitsett Vision Group, Houston

77204

The Ocular Surface Institute (TOSI), University of Houston, Houston

77566

Brazosport Eye Institute, Lake Jackson

78230

Kozlovsky Delay & Winter Eye Consultants, LLC, San Antonio

78731

Texan Eye, PA / Keystone Research, Ltd, Austin

79902

The Cataract and Glaucoma Center, El Paso

84020

Hoopes Vision, Draper

85225

Arizona Eye Center, Chandler

89148

Abrams Eye Institute, Las Vegas

90048

Macy Eye Center, Los Angeles

90067

Advanced Vision Care, Los Angeles

90505

Wolstan & Goldberg Eye Associates, Torrance

90701

Sall Research Medical Center, Artesia

91204

Lugene Eye Institute, Glendale

91702

Milton M. Hom, OD, FAAO, Azusa

92064

Arch Health Partners, Poway

92115

West Coast Eye Care Associates, San Diego

92663

Eye Research Foundation, Newport Beach

92683

Michael K Tran, M.D., Inc., Westminster

92843

Orange County Ophthalmology, Garden Grove

95008

Family Eye Care Center, Campbell

95670

Martel Eye Medical Group, Rancho Cordova

96002

Shasta Eye Medical Group, Inc, Redding

97401

Drs. Fine, Hoffman & Sims, LLC, Eugene

99204

Spokane Eye Clinical Research, Spokane

35294-0010

UAB School of Optometry, Birmingham

92697-4375

The Gavin Herbert Eye Institute, Irvine

Unknown

North Valley Eye Medical Group, Mission Hills

02114

Ophthalmic Consultants of Boston, Boston

Sponsors
All Listed Sponsors
lead

Kala Pharmaceuticals, Inc.

INDUSTRY

NCT02819284 - Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease | Biotech Hunter | Biotech Hunter